Lantheus Holdings Stock Fair Value – Lantheus Holdings Reports Impressive 18% Revenue Growth in Third Quarter 2024
November 13, 2024
☀️Trending News
Lantheus Holdings ($NASDAQ:LNTH) is a global medical imaging company that specializes in developing, manufacturing, and commercializing innovative diagnostic and therapeutic products. The company’s portfolio includes a wide range of contrast agents, radiopharmaceuticals, and medical devices used in the diagnosis and treatment of various diseases. In recent years, Lantheus Holdings has experienced significant growth and success, solidifying its position as a leader in the healthcare industry. The latest financial results for the third quarter of 2024 further demonstrate the company’s strong performance and potential for continued growth. One of the key highlights of the report is the impressive 18% increase in revenue compared to the same quarter in 2023. This significant growth can be attributed to several factors, including the successful launch of new products and increased demand for existing ones.
Additionally, the company’s expansion into new markets has also contributed to the increase in revenue. In addition to financial success, Lantheus Holdings has also made significant progress in advancing its pipeline of products. The company received FDA approval for two new molecular imaging agents in the third quarter of 2024, further expanding its portfolio and providing more options for healthcare providers and patients. Overall, Lantheus Holdings has continued to deliver impressive results and solidify its position as a leading player in the medical imaging industry. With a strong financial performance and a promising pipeline of products, the company is well-positioned for future growth and success. Investors can expect to see continued positive developments from Lantheus Holdings in the coming quarters.
Analysis – Lantheus Holdings Stock Fair Value
As a financial analyst at GoodWhale, I have examined the financial statements of LANTHEUS HOLDINGS and have come to some key points. Firstly, based on our proprietary Valuation Line, we have calculated the fair value of LANTHEUS HOLDINGS share to be around $88.1. This indicates that the current trading price of $87.5 is relatively close to the fair value, making it a fair price for investors. In order to determine the fair value, we have taken into consideration various factors such as the company’s financial performance, market trends, and industry comparisons. Our analysis suggests that LANTHEUS HOLDINGS is performing well financially and is in a strong position compared to its competitors. This is reflected in the fair value calculation and supports our conclusion that the current trading price is fair. Investors should also take note that LANTHEUS HOLDINGS has consistently shown growth and profitability in recent years, which further adds to its attractiveness as an investment opportunity. The company has a strong pipeline of new products and continues to invest in research and development, which bodes well for its future prospects. In summary, based on our analysis, LANTHEUS HOLDINGS appears to be a sound investment choice at its current trading price of $87.5. With a fair value of $88.1, investors can feel confident that they are paying a reasonable price for the company’s shares. However, as with any investment, it is important to consider other factors such as personal risk tolerance and overall market conditions before making a decision. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Lantheus Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 1.3k | 326.66 | 22.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Lantheus Holdings. More…
| Operations | Investing | Financing |
| 305.26 | 5.94 | -13.06 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Lantheus Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.65k | 835.26 | 11.91 |
Key Ratios Snapshot
Some of the financial key ratios for Lantheus Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 56.3% | -11.2% | 33.2% |
| FCF Margin | ROE | ROA |
| 20.0% | 35.6% | 16.3% |
Peers
The company operates through two segments, Diagnostic Imaging and Therapeutic Imaging. The Diagnostic Imaging segment provides contrast media products and related services used in diagnostic imaging procedures. The Therapeutic Imaging segment provides nuclear imaging products and services used in molecular and nuclear medicine procedures. Lantheus Holdings Inc’s competitors include RadNet Inc, Akumin Inc, and Todos Medical Ltd. RadNet Inc is a provider of outpatient diagnostic imaging services in the United States. Akumin Inc is a provider of diagnostic imaging services in the United States and Canada. Todos Medical Ltd is a biotechnology company that develops and commercializes blood tests for the early detection of cancer.
– RadNet Inc ($NASDAQ:RDNT)
RadNet, Inc. is a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2020, RadNet operated a network of 284 outpatient imaging centers located in California, Delaware, Maryland, Massachusetts, New Jersey, New York and Virginia. RadNet’s core business is providing high-quality diagnostic imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, digital x-ray, diagnostic radiology and fluoroscopy, at its outpatient imaging centers.
– Akumin Inc ($NASDAQ:AKU)
Akumin Inc is a holding company that, through its subsidiaries, provides outpatient diagnostic imaging services in the United States. It operates through the following segments: Imaging Centers and Mobile Imaging. The Imaging Centers segment consists of fixed-site imaging centers that provide magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, general x-ray, and diagnostic cardiology services. The Mobile Imaging segment acquires, leases, and operates mobile imaging equipment that provides magnetic resonance imaging, computed tomography, ultrasound, and general x-ray services. The company was founded on December 12, 2005 and is headquartered in Dallas, TX.
– Todos Medical Ltd ($OTCPK:TOMDF)
Todos Medical Ltd has a market cap of 19.09M as of 2022, a Return on Equity of 43.06%. The company is engaged in the business of providing diagnostic products and services for the early detection, diagnosis and prognosis of cancer and other diseases. The company’s products and services include blood tests, tissue tests and imaging services. The company’s blood tests are used to detect the presence of cancer cells in the blood, while its tissue tests are used to detect the presence of cancer cells in the tissue. The company’s imaging services are used to detect the presence of cancer cells in the body.
Summary
Lantheus Holdings has reported strong financial results for the third quarter of 2024, with revenue increasing by 18% compared to the same period last year. This growth is a positive sign for investors, indicating a healthy and profitable business. Furthermore, this growth suggests that Lantheus Holdings is successfully executing its business strategies and expanding its market share.
Investors should take note of this positive performance and consider the potential for future growth in the company. With steady revenue growth and a strong market position, Lantheus Holdings presents a promising investment opportunity in the healthcare sector.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
